Carr J Smith

Summary

Affiliation: Research and Development
Country: USA

Publications

  1. ncbi Environmental tobacco smoke, cardiovascular disease, and the nonlinear dose-response hypothesis
    C J Smith
    Research and Development Department, Bowman Gray Technical Center, R J Reynolds Tobacco Company, Winston Salem, North Carolina 27102, USA
    Toxicol Sci 54:462-72. 2000
  2. ncbi Urinary mutagenicity in nonsmokers following exposure to fresh diluted sidestream cigarette smoke
    C J Smith
    Research and Development, R J Reynolds Tobacco Company, Winston Salem, NC 27102 1487, USA
    Mutat Res 470:53-70. 2000
  3. ncbi Urinary thromboxane, prostacyclin, cortisol, and 8-hydroxy-2'-deoxyguanosine in nonsmokers exposed and not exposed to environmental tobacco smoke
    C J Smith
    Research and Development, R J Reynolds Tobacco Company, Bowman Gray Technical Center, Winston Salem, North Carolina 27102, USA
    Toxicol Sci 59:316-23. 2001
  4. ncbi "IARC Group 2B carcinogens" reported in cigarette mainstream smoke
    C J Smith
    Research and Development, Bowman Gray Technical Center, R J Reynolds Tobacco Company, Winston Salem, NC 27102, USA
    Food Chem Toxicol 39:183-205. 2001
  5. ncbi Particulate and vapor phase constituents of cigarette mainstream smoke and risk of myocardial infarction
    C J Smith
    Research and Development, Bowman Gray Technical Center, R J Reynolds Tobacco Company, Winston Salem, NC 27102, USA
    Atherosclerosis 158:257-67. 2001
  6. ncbi The relative toxicity of substituted phenols reported in cigarette mainstream smoke
    Carr J Smith
    R and D, Bowman Gray Technical Center, RJRT Company, Winston Salem, North Carolina 27102 1487, USA
    Toxicol Sci 69:265-78. 2002
  7. ncbi Percutaneous penetration enhancers in cigarette mainstream smoke
    Carr J Smith
    R and D, Research and Development, RJ Reynolds Tobacco Company, Bowman Gray Technical Center, RJRT Company, Winston Salem, NC 27102 1487, USA
    Food Chem Toxicol 42:9-15. 2004
  8. ncbi IARC carcinogens reported in cigarette mainstream smoke and their calculated log P values
    C J Smith
    R and D, Bowman Gray Technical Center, RJRT Company, Winston Salem, NC 27102 1487, USA
    Food Chem Toxicol 41:807-17. 2003
  9. ncbi Relationship between FTC 'tar' and urine mutagenicity in smokers of tobacco-burning or Eclipse cigarettes
    Denise L Bowman
    R J Reynolds Tobacco Company, Research and Development, Product Evaluation Group, Winston Salem, NC 27102, USA
    Mutat Res 521:137-49. 2002
  10. ncbi Utility of the mouse dermal promotion assay in comparing the tumorigenic potential of cigarette mainstream smoke
    Carr J Smith
    Department of Pathology, University of South Alabama College of Medicine, Mobile, 36617 2293, USA
    Food Chem Toxicol 44:1699-706. 2006

Collaborators

Detail Information

Publications12

  1. ncbi Environmental tobacco smoke, cardiovascular disease, and the nonlinear dose-response hypothesis
    C J Smith
    Research and Development Department, Bowman Gray Technical Center, R J Reynolds Tobacco Company, Winston Salem, North Carolina 27102, USA
    Toxicol Sci 54:462-72. 2000
    ..Proximal thrombogenic risk markers identified in field studies should be mechanistically examined under controlled exposure conditions...
  2. ncbi Urinary mutagenicity in nonsmokers following exposure to fresh diluted sidestream cigarette smoke
    C J Smith
    Research and Development, R J Reynolds Tobacco Company, Winston Salem, NC 27102 1487, USA
    Mutat Res 470:53-70. 2000
    ..05) in urinary mutagenicity in strain YG1024, but not in the less sensitive strain TA98 on the day of FDSS exposure...
  3. ncbi Urinary thromboxane, prostacyclin, cortisol, and 8-hydroxy-2'-deoxyguanosine in nonsmokers exposed and not exposed to environmental tobacco smoke
    C J Smith
    Research and Development, R J Reynolds Tobacco Company, Bowman Gray Technical Center, Winston Salem, North Carolina 27102, USA
    Toxicol Sci 59:316-23. 2001
    ..Therefore, platelet aggregation is not a plausible or quantitatively consistent mechanism to explain the nonlinear dose-response hypothesis of cardiovascular disease and ETS exposure...
  4. ncbi "IARC Group 2B carcinogens" reported in cigarette mainstream smoke
    C J Smith
    Research and Development, Bowman Gray Technical Center, R J Reynolds Tobacco Company, Winston Salem, NC 27102, USA
    Food Chem Toxicol 39:183-205. 2001
    ....
  5. ncbi Particulate and vapor phase constituents of cigarette mainstream smoke and risk of myocardial infarction
    C J Smith
    Research and Development, Bowman Gray Technical Center, R J Reynolds Tobacco Company, Winston Salem, NC 27102, USA
    Atherosclerosis 158:257-67. 2001
    ..Finally, the arrhythmia-inducing potential may result from catecholamine release following nicotine exposure, with a questionable contribution from carbon monoxide...
  6. ncbi The relative toxicity of substituted phenols reported in cigarette mainstream smoke
    Carr J Smith
    R and D, Bowman Gray Technical Center, RJRT Company, Winston Salem, North Carolina 27102 1487, USA
    Toxicol Sci 69:265-78. 2002
    ..Studies of this type can play an important role in identifying MS components for reduction or removal...
  7. ncbi Percutaneous penetration enhancers in cigarette mainstream smoke
    Carr J Smith
    R and D, Research and Development, RJ Reynolds Tobacco Company, Bowman Gray Technical Center, RJRT Company, Winston Salem, NC 27102 1487, USA
    Food Chem Toxicol 42:9-15. 2004
    ....
  8. ncbi IARC carcinogens reported in cigarette mainstream smoke and their calculated log P values
    C J Smith
    R and D, Bowman Gray Technical Center, RJRT Company, Winston Salem, NC 27102 1487, USA
    Food Chem Toxicol 41:807-17. 2003
    ....
  9. ncbi Relationship between FTC 'tar' and urine mutagenicity in smokers of tobacco-burning or Eclipse cigarettes
    Denise L Bowman
    R J Reynolds Tobacco Company, Research and Development, Product Evaluation Group, Winston Salem, NC 27102, USA
    Mutat Res 521:137-49. 2002
    ..The reduction in urine mutagenicity when smoking Eclipse provides supporting evidence that Eclipse may present less risk of cancer compared to cigarettes currently in the market...
  10. ncbi Utility of the mouse dermal promotion assay in comparing the tumorigenic potential of cigarette mainstream smoke
    Carr J Smith
    Department of Pathology, University of South Alabama College of Medicine, Mobile, 36617 2293, USA
    Food Chem Toxicol 44:1699-706. 2006
    ....
  11. ncbi Perspectives on pulmonary inflammation and lung cancer risk in cigarette smokers
    Carr J Smith
    Department of Pathology, University of South Alabama College of Medicine, Mobile, Alabama, USA
    Inhal Toxicol 18:667-77. 2006
    ....
  12. ncbi Changes in markers of epithelial permeability and inflammation in chronic smokers switching to a nonburning tobacco device (Eclipse)
    Judith C Stewart
    Department of Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
    Nicotine Tob Res 8:773-83. 2006
    ..Switching to Eclipse reduces alveolar epithelial injury in some smokers but may increase carboxyhemoglobin levels and oxidative stress...